{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:32:05Z","timestamp":1790922725442,"version":"4.1.0"},"reference-count":135,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>\n            Carbapenem-resistant\n            <jats:named-content content-type=\"genus-species\">Acinetobacter baumannii<\/jats:named-content>\n            (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels.\n          <\/jats:p>","DOI":"10.1128\/aac.01110-18","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T11:03:53Z","timestamp":1539169433000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":257,"title":["New Treatment Options against Carbapenem-Resistant\n            <i>Acinetobacter baumannii<\/i>\n            Infections"],"prefix":"10.1128","volume":"63","author":[{"given":"Burcu","family":"Isler","sequence":"first","affiliation":[{"name":"Istanbul Education and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University Veterans Affairs Center of Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[{"name":"The University of Queensland Centre for Clinical Research, Royal Brisbane and Women\u2019s Hospital Campus, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-07"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-16"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01728-10"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00006-08"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks084"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.09.025"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ048"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30099-9"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1017\/S095026881200194X"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit253"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02435-13"},{"key":"e_1_3_1_15_2","unstructured":"Kaye K. 2012. Trial for the treatment of extensively drug-resistant Gram-negative bacilli. Accession no. NCT01597973. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01597973?term=NCT01597973&rank=1."},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-006-0123-1"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp342"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.05.012"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.10.033"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00931-17"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.11.011"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0153-2"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01524-16"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02636-14"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw829"},{"key":"e_1_3_1_26_2","unstructured":"Nektar Therapeutics. 2013. Inhaled amikacin solution BAY41-6551 as adjunctive therapy in the treatment of Gram-negative pneumonia (INHALE 1). Accession no. NCT01799993. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01799993."},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0267-8"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540600951184"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.06.022"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx368"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw377"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep17091"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku168"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00963-13"},{"key":"e_1_3_1_35_2","first-page":"658","volume-title":"Kucers\u2019 the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral Drugs","author":"Paterson DL","year":"2017","unstructured":"Paterson DL. 2017. Antibiotics: cephalosporins and related drugs: cefiderocol, p 658\u2013663. In Grayson LM, Cosgrove SE, Crowe S, Hope W, McCarthy JS, Mills J, Mouton JW, Paterson DL (ed), Kucers\u2019 the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral Drugs, vol 1, 7th ed. CRC Press, Boca Raton, FL."},{"key":"e_1_3_1_36_2","volume-title":"Abstr 28th Eur Cong Clin Microbiol Infect Dis","author":"Jacobs M","year":"2018","unstructured":"Jacobs M, Bajaksouzian S, Good C, Hujer K, Hujer A, Bonomo RA. 2018. In vitro activity of cefiderocol (S-649266), a siderophore cephalosporin, against carbapenem-susceptible and resistant non-fermenting Gram-negative bacteria, abstr P-0187. Abstr 28th Eur Cong Clin Microbiol Infect Dis, 21 to 24 April 2018, Madrid, Spain."},{"key":"e_1_3_1_37_2","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-non-susceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014\u20132016","volume":"20","author":"Hackel MA","year":"2017","unstructured":"Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. 2017. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-non-susceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014\u20132016. Antimicrob Agents Chemother 20:e01968-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00093-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem non-susceptible isolates: the SIDERO-WT-2014 study","volume":"9","author":"Hackel MA","year":"2017","unstructured":"Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. 2017. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem non-susceptible isolates: the SIDERO-WT-2014 study. Antimicrob Agents Chemother 9:e00093-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-3063-z"},{"key":"e_1_3_1_40_2","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"23","author":"Ito A","year":"2017","unstructured":"Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R. 2017. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 23:e01454-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv402"},{"key":"e_1_3_1_42_2","volume-title":"ASM Microbe","author":"Tsuji M","year":"2017","unstructured":"Tsuji M, Kazmierczak KM, Hackel M, Echols R, Yamano Y, Sahm DF. 2017. Cefiderocol (S-649266) susceptibility against globally isolated meropenem non-susceptible Gram-negative bacteria containing serine- and metallo-carbapenemase genes, abstr SUNDAY-25. ASM Microbe, 1 to 5 June 2017, New Orleans, LA."},{"key":"e_1_3_1_43_2","volume-title":"ASM Microbe","author":"Tsuji M","year":"2017","unstructured":"Tsuji M, Hackel M, Echols R, Yamano Y, Sahm DF. 2017. In vitro antibacterial activity of cefiderocol (S-649266) against Gram-negative clinical strains collected in North America and Europe: SIDERO-WT-2015, abstr SUNDAY-11. ASM Microbe, 1 to 5 June 2017, New Orleans, LA."},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","unstructured":"Boyd S Anderson K Albrecht V Campbell D Karlsson MS Rasheed KJ. 2017. In vitro activity of cefiderocol against multi-drug resistant carbapenemase-producing Gram-negative pathogens abstr 1230. IDWeek 2017 4 to 8 October 2017 San Diego CA.","DOI":"10.1093\/ofid\/ofx163.926"},{"key":"e_1_3_1_45_2","volume-title":"ASM Microbe","author":"Ito A","year":"2017","unstructured":"Ito A, Miyagawa S, Ishibashi N, Nishikawa T, Kohira N, Sato T, Tsuji M, Yamano Y. 2017. Anti-Acinetobacter activity of cefiderocol (S-649266), a novel siderophore cephalosporin: bactericidal activity due to penicillin-binding proteins inhibition and antibacterial activity against globally collected clinical isolates, abstr SATURDAY-115. ASM Microbe, 1 to 5 June 2017, New Orleans, LA."},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx049"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00700-17"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01022-17"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1399"},{"key":"e_1_3_1_50_2","unstructured":"Shionogi Inc. 2016. Study of S-649266 or best available therapy for the treatment of severe infections caused by carbapenem-resistant Gram-negative pathogens (CREDIBLE-CR). Accession no. NCT02714595. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02714595."},{"key":"e_1_3_1_51_2","unstructured":"Shionogi Inc. 2017. Clinical study of S-649266 for the treatment of nosocomial pneumonia caused by Gram-negative pathogens (APEKS-NP). Accession no. NCT03032380. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03032380."},{"key":"e_1_3_1_52_2","volume-title":"ASM Microbe","author":"Hackel M","year":"2017","unstructured":"Hackel M, Butler D, Miller L, Bouchillon S, Sahm D. 2017. In vitro antibacterial activity of GSK3342830 against a global collection of clinically relevant Gram-negative bacteria, abstr SATURDAY-288. ASM Microbe, 1 to 5 June 2017, New Orleans, LA."},{"key":"e_1_3_1_53_2","volume-title":"ASM Microbe","author":"Rhomberg PR","year":"2017","unstructured":"Rhomberg PR, Shortridge D, Huband MD, Butler D, West J, Flamm RK. 2017. Multilaboratory broth microdilution MIC reproducibility study for GSK3342830, a novel catechol-cephem, abstr SATURDAY-287. ASM Microbe, 1 to 5 June 2017, New Orleans, LA."},{"key":"e_1_3_1_54_2","unstructured":"GlaxoSmithKline. 2016. A study to evaluate safety tolerability and pharmacokinetics of ascending intravenous single dose and repeat dose of GSK3342830. Accession no. NCT02751424. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02751424?cond=GSK3342830&rank=1."},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00102"},{"key":"e_1_3_1_57_2","volume-title":"Abstr 28th Eur Cong Clin Microbiol Infect Dis","author":"Olesky M","year":"2018","unstructured":"Olesky M, Morrissey I, Hawser S, Magnet S, Guemmaz A, Monti F, Fyfe C, Bassetti M. 2018. In vitro activity of eravacycline and comparators against resistant Gram negative isolates collected in 2016 from patients in Europe, abstr P-0099. Abstr 28th Eur Cong Clin Microbiol Infect Dis, 21 to 24 April 2018, Madrid, Spain."},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00436-16"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04809-14"},{"key":"e_1_3_1_60_2","volume-title":"Abstr 28th Eur Cong Clin Microbiol Infect Dis","author":"Fyfe C","year":"2018","unstructured":"Fyfe C, Barry R, Close B, Kerstein K, Nordmann P, Newman J. 2018. Eravacycline is active against bacterial isolates carrying emergent resistance types, abstr P-1156. Abstr 28th Eur Cong Clin Microbiol Infect Dis, 21 to 24 April 2018, Madrid, Spain."},{"key":"e_1_3_1_61_2","doi-asserted-by":"crossref","unstructured":"Bassetti M Corey R Doi Y Morrissey I Grossman T Olesky M Sutcliffe J. 2016. In vitro global surveillance of eravacycline and comparators against Enterobacteriaceae Acinetobacter baumannii Stenotrophomonas maltophilia including multidrug-resistant (MDR) isolates over a three-year period (2013-15) abstr 1825. IDWeek 2016 26 to 30 October 2017 New Orleans LA.","DOI":"10.1093\/ofid\/ofw172.1373"},{"key":"e_1_3_1_62_2","volume-title":"Abstr 27th Eur Cong Clin Microbiol Infect Dis","author":"El-Bouseary M","year":"2017","unstructured":"El-Bouseary M, Tyrrell J, Walsh TR, Olesky M. 2017. Eravacycline, a novel fluorocycline, has antibacterial activity against carbapenemresistant Enterobacteriaceae (CRE) and Acinetobacter spp. (CRA), abstr P-1259. Abstr 27th Eur Cong Clin Microbiol Infect Dis, 22 to 25 April 2017, Vienna, Austria."},{"key":"e_1_3_1_63_2","volume-title":"Abstr 27th Eur Cong Clin Microbiol Infect Dis","author":"El-Bouseary M","year":"2017","unstructured":"El-Bouseary M, Tyrrell J, Walsh TR, Olesky M. 2017. Antibacterial activity of eravacycline, a novel fluorocycline, compared to established antimicrobials, against contemporary clinical isolates from Tanta, Egypt, abstr P-1261. Abstr 27th Eur Cong Clin Microbiol Infect Dis, 22 to 25 April 2017, Vienna, Austria."},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_3_1_66_2","volume-title":"Abstr 28th Eur Cong Clin Microbiol Infect Dis","author":"Horn P","year":"2018","unstructured":"Horn P, Tsai L, Solomkin J, Evans D, Gardovskis J. 2018. Results of IGNITE4: a phase-3 study to evaluate the efficacy and safety of eravacycline versus meropenem in complicated intra-abdominal infections. abtr O0421. Abstr 28th Eur Cong Clin Microbiol Infect Dis, 21 to 24 April 2018, Madrid, Spain."},{"key":"e_1_3_1_68_2","volume-title":"Abstr 27th Eur Cong Clin Microbiol Infect Dis","author":"Seifert H","year":"2017","unstructured":"Seifert H, Stefanik D, Sutcliffe J, Higgins PG. 2017. In-vitro activity of the novel fluorocycline TP-6076 against carbapenem non-susceptible Acinetobacter baumannii, abstr P-1364. Abstr 27th Eur Cong Clin Microbiol Infect Dis, 22 to 25 April 2017, Vienna, Austria."},{"key":"e_1_3_1_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.03.009"},{"key":"e_1_3_1_70_2","volume-title":"Abstr 27th Eur Cong Clin Microbiol Infect Dis","author":"Grossman T","year":"2017","unstructured":"Grossman T, Fyfe C, Kerstein K, Xiao XY, Sun C, Newman J, Nguyen P, Pulse M, Weiss W, Dumas J, Sutcliffe J. 2017. TP-6076 is efficacious in a mouse pneumonia model with carbapenem-resistant Acinetobacter baumannii (CRAB) and retains potency against common tetracycline-resistance mechanisms, abstr P-1310. Abstr 27th Eur Cong Clin Microbiol Infect Dis, 22 to 25 April 2017, Vienna, Austria."},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00091"},{"key":"e_1_3_1_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"e_1_3_1_74_2","unstructured":"Hackel M Bouchillon S deJonge B Lawrence K Mueller J Tommasi R Miller A. 2016. Global surveillance of the activity of sulbactam combined with the novel \u03b2-lactamase inhibitor ETX2514 against clinical isolates of Acinetobacter baumannii from 2014 abstr 2243. IDWeek 2016 26 to 30 October 2017 New Orleans LA."},{"key":"e_1_3_1_75_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01576-17"},{"key":"e_1_3_1_76_2","volume-title":"Abstr 27th Eur Cong Clin Microbiol Infect Dis","author":"Tommasi R","year":"2017","unstructured":"Tommasi R, Tanudra A, Chen A, Mueller J, O\u2019Donnell J. 2017. ETX2514: responding to the global threat of nosocomial multidrug and extremely drug-resistant Gram-negative pathogens, abstr OS-0559. Abstr 27th Eur Cong Clin Microbiol Infect Dis, 22 to 25 April 2017, Vienna, Austria."},{"key":"e_1_3_1_77_2","unstructured":"Entasis Therapeutics. 2016. Evaluation of the safety tolerability and pharmacokinetics of intravenous ETX2514 administered in healthy subjects. Accession no. NCT02971423. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02971423."},{"key":"e_1_3_1_78_2","doi-asserted-by":"crossref","unstructured":"Lickliter J Lawrence K O\u2019Donnell J Isaacs R. 2017. Safety and pharmacokinetics (PK) in humans of intravenous ETX2514 a \u03b2-lactamase inhibitor (BLI) which broadly inhibits Ambler class A C and D \u03b2-lactamases abstr 1836. IDWeek 2017 4 to 8 October 2017 San Diego CA.","DOI":"10.1093\/ofid\/ofx163.1366"},{"key":"e_1_3_1_79_2","unstructured":"Entasis Therapeutics. 2017. Study to determine and compare plasma and intrapulmonary concentrations of ETX2514 and sulbactam in healthy subjects. Accession no. NCT03303924. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03303924?term=NCT03303924&rank=1."},{"key":"e_1_3_1_80_2","unstructured":"Entasis Therapeutics. 2017. Evaluation of the pharmacokinetics safety and tolerability of intravenous ETX2514 and sulbactam administered concurrently to subjects with various degrees of renal impairment and healthy matched control subjects. Accession no. NCT03310463. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03310463?term=NCT03310463&rank=1."},{"key":"e_1_3_1_81_2","unstructured":"Entasis Therapeutics. 2018. Evaluation of safety and efficacy of intravenous sulbactam-ETX2514 in the treatment of hospitalized adults with complicated urinary tract infections. Accession no. NCT03445195. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03445195?term=NCT03445195&rank=1."},{"key":"e_1_3_1_82_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx035"},{"key":"e_1_3_1_83_2","volume-title":"ASM Microbe","author":"Castanheira M","year":"2016","unstructured":"Castanheira M, Rhomberg PR, Lindley JM, Jones RN, Sader HS. 2016. Activity of the new carbapenem\/\u03b2-lactamase inhibitor combination WCK 5999 against Gram-negative isolates producing oxacillinases (OXAs), abstr MONDAY-422. ASM Microbe, 16 to 20 June 2016, Boston, MA."},{"key":"e_1_3_1_84_2","volume-title":"ASM Microbe","author":"Sader HS","year":"2017","unstructured":"Sader HS, Flamm RK, Huband MD, Rhomberg PR, Castanheira M. 2017. Antimicrobial activity of meropenem-WCK 4234 (WCK 5999) against clinical isolates of Acinetobacter spp. collected worldwide and stratified by infection type, abstr SATURDAY-97. ASM Microbe, 1 to 5 June 2017, New Orleans, LA."},{"key":"e_1_3_1_85_2","volume-title":"ASM Microbe","author":"Huband MD","year":"2016","unstructured":"Huband MD, Farrell DJ, Flamm RK, Jones RN, Sader HS. 2016. In vitro activity of WCK 5999 against Acinetobacter baumannii and Pseudomonas aeruginosa isolates from a worldwide surveillance program (2015), abstr FRIDAY-476. ASM Microbe, 16 to 20 June 2016, Boston, MA."},{"key":"e_1_3_1_86_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01172-17"},{"key":"e_1_3_1_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw105"},{"key":"e_1_3_1_89_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01238-17"},{"key":"e_1_3_1_90_2","volume-title":"Abstr 28th Eur Cong Clin Microbiol Infect Dis","author":"Moya B","year":"2017","unstructured":"Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Oliver A. 2017. Zidebactam (WCK 5107) and WCK 5153: bicyclo-acyl hydrazide penicillin-bindingprotein (PBP) inhibitors showing potent beta-lactam enhancer activity against multidrug-resistant (MDR) metallo-beta-lactamase (MBL)-producing Klebsiella pneumoniae, abstr P-1300. Abstr 28th Eur Cong Clin Microbiol Infect Dis, 21 to 24 April 2018, Madrid, Spain."},{"key":"e_1_3_1_91_2","unstructured":"Wockhardt. 2016. MED study to evaluate the safety tolerability and pharmacokinetics of intravenous WCK 5222 (zidebactam and cefepime) in healthy volunteers. Accession no. NCT02707107. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02707107."},{"key":"e_1_3_1_92_2","unstructured":"Wockhardt. 2015. Study to evaluate the safety tolerability and pharmacokinetics of WCK 5107 alone and in combination with cefepime. Accession no. NCT02532140. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02532140."},{"key":"e_1_3_1_93_2","unstructured":"Wockhardt. 2016. To investigate the pharmacokinetics of intravenous WCK 5222 (FEP-ZID) in patients with renal impairment. Accession no. NCT02942810. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02942810."},{"key":"e_1_3_1_95_2","volume-title":"Abstr 53r Intersci Conf Antimicrob Agents Chemother","author":"Joo HY","year":"2013","unstructured":"Joo HY, Kim DI, Kowalik E, Li Y, Mao S, Liu S, Hager MW, Choi WB. 2013. FSI-1671, a novel anti-Acinetobacter carbapenem; in vitro activities of FSI-1671 and FSI-1671\/sulbactam against MDR-A. baumannii, abstr F-1202. Abstr 53r Intersci Conf Antimicrob Agents Chemother, 10 to 13 September 2013, Denver, CO."},{"key":"e_1_3_1_96_2","volume-title":"Abstr 53r Intersci Conf Antimicrob Agents Chemother","author":"Joo HY","year":"2013","unstructured":"Joo HY, Kim DI, Kowalik E, Li Y, Mao S, Liu S, Hager MW, Choi WB. 2013. FSI-1671, a novel anti-Acinetobacter carbapenem; in vivo efficacy against carbapenem-resistance Gram-negative bacterial infection, abstr F-1201. Abstr 53r Intersci Conf Antimicrob Agents Chemother, 10 to 13 September 2013, Denver, CO."},{"key":"e_1_3_1_97_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01239-17"},{"key":"e_1_3_1_98_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00200-17"},{"key":"e_1_3_1_99_2","volume-title":"ASM Microbe","author":"Mendes RE","year":"2016","unstructured":"Mendes RE, Rhomberg PR, Becker HK, Davis AP, Lister T, Parr TR, Vaara M, Flamm RK. 2016. Synergistic effect of Gram-positive agents tested in combination with a new polymyxin derivative (SPR741) against multidrug-resistant Gram-negative pathogens, abstr SATURDAY-490. ASM Microbe, 16 to 20 June 2016, Boston, MA."},{"key":"e_1_3_1_100_2","volume-title":"Abstr 27th Eur Cong Clin Microbiol Infect Dis","author":"Warn P","year":"2017","unstructured":"Warn P, Teague J, Corbett D, Payne L, Burgess E. 2017. In-vivo efficacy of combinations of novel antimicrobial peptide SPR741 and rifampicin in neutropenic murine thigh infection models of Gram-negative bacterial infection, abstr OS-0563. Abstr 27th Eur Cong Clin Microbiol Infect Dis, 22 to 25 April 2017, Vienna, Austria."},{"key":"e_1_3_1_101_2","volume-title":"Abstr 28th Eur Cong Clin Microbiol Infect Dis","author":"Utley L","year":"2018","unstructured":"Utley L, Lister T, Coleman S, Eckburg P. 2018. Determination of the pharmacokinetics of single (SAD) and multiple ascending doses (MAD) of SPR741 in healthy volunteers, abstr P-2233. Abstr 28th Eur Cong Clin Microbiol Infect Dis, 21 to 24 April 2018, Madrid, Spain."},{"key":"e_1_3_1_102_2","volume-title":"Abstr 28th Eur Cong Clin Microbiol Infect Dis","author":"Keutzer T","year":"2018","unstructured":"Keutzer T, Eckburg P, Farinola N, Walpole S, Utley L, Dwyer J, Kopp E, Coleman S, Tomayko J. 2018. Safety of SPR741, a novel polymyxin potentiator, in healthy adults receiving single- and multiple-dose intravenous administrations, abstr P-2206. Abstr 28th Eur Cong Clin Microbiol Infect Dis, 21 to 24 April 2018, Madrid, Spain."},{"key":"e_1_3_1_103_2","volume-title":"ASM Microbe","author":"Rubio-Aparicio D","year":"2016","unstructured":"Rubio-Aparicio D, Nelson K, Roberts KD, Thompson PE, Nation RL, Velkov T, Li J, Hecker SJ, Grif\ufb01th DC, Dudley MN, Lomovskaya O. 2016. In vitro activity of FADDI-287, a representative of a novel series of polymyxins (PM) with reduced nephrotoxic potential, abstr SATURDAY-495. ASM Microbe, 16 to 20 June 2016, Boston, MA."},{"key":"e_1_3_1_104_2","volume-title":"ASM Microbe","author":"Sabet M","year":"2016","unstructured":"Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Roberts KD, Thompson PE, Nation RL, Velkov T, Li J, Hecker SJ, Lomovskaya O, Dudley MN, Grif\ufb01th DC. 2016. Pharmacology of the novel polymyxin FADDI-287 in preclinical models, abstr SATURDAY-499. ASM Microbe, 16 to 20 June 2016, Boston, MA."},{"key":"e_1_3_1_105_2","volume-title":"Abstr 28th Eur Cong Clin Microbiol Infect Dis","author":"Galani I","year":"2018","unstructured":"Galani I, Nafplioti K, Chatzikonstantinou M, Giamarellou H, Souli M. 2018. Evaluation of apramycin activity against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii, abstr P-0096. Abstr 28th Eur Cong Clin Microbiol Infect Dis, 21 to 24 April 2018, Madrid, Spain."},{"key":"e_1_3_1_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.03.006"},{"key":"e_1_3_1_107_2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02585-17","article-title":"Efficacy of apramycin against multidrug-resistant Acinetobacter baumannii in the murine neutropenic thigh model","volume":"16","author":"Kang AD","year":"2018","unstructured":"Kang AD, Smith KP, Berg AH, Truelson KA, Eliopoulos GM, McCoy C, Kirby JE. 2018. Efficacy of apramycin against multidrug-resistant Acinetobacter baumannii in the murine neutropenic thigh model. Antimicrob Agents Chemother 16:e02585-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_1_108_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00407-16"},{"key":"e_1_3_1_109_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw210"},{"key":"e_1_3_1_110_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00674-17"},{"key":"e_1_3_1_111_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1360282"},{"key":"e_1_3_1_112_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04840-14"},{"key":"e_1_3_1_113_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00284-016-1166-x"},{"key":"e_1_3_1_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resmic.2010.03.007"},{"key":"e_1_3_1_115_2","doi-asserted-by":"publisher","DOI":"10.1371\/annotation\/86d9f6df-7175-467c-a9ff-94eac53af128"},{"key":"e_1_3_1_116_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.02659"},{"key":"e_1_3_1_117_2","doi-asserted-by":"publisher","DOI":"10.1159\/000486117"},{"key":"e_1_3_1_118_2","first-page":"523","article-title":"Therapeutic effect of phages on extensively drug-resistant Acinetobacter baumannii-induced sepsis in mice","volume":"32","author":"Deng LY","year":"2016","unstructured":"Deng LY, Yang ZC, Gong YL, Huang GT, Yin SP, Jiang B, Peng YZ. 2016. Therapeutic effect of phages on extensively drug-resistant Acinetobacter baumannii-induced sepsis in mice. Zhonghua Shao Shang Za Zhi 32:523\u2013528. (In Chinese.)","journal-title":"Zhonghua Shao Shang Za Zhi"},{"key":"e_1_3_1_119_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01590"},{"key":"e_1_3_1_120_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02877-15"},{"key":"e_1_3_1_121_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04641-14"},{"key":"e_1_3_1_122_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2014.0120"},{"key":"e_1_3_1_123_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00954-17"},{"key":"e_1_3_1_124_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy064"},{"key":"e_1_3_1_125_2","doi-asserted-by":"publisher","DOI":"10.4161\/bact.1.2.15845"},{"key":"e_1_3_1_126_2","doi-asserted-by":"publisher","DOI":"10.20953\/1729-9225-2017-1-35-40"},{"key":"e_1_3_1_127_2","doi-asserted-by":"publisher","DOI":"10.1080\/21597081.2016.1251379"},{"key":"e_1_3_1_128_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.01271"},{"key":"e_1_3_1_129_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-017-0283-6"},{"key":"e_1_3_1_130_2","unstructured":"Kessler T. 2017. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate. Accession no. NCT03140085. ClinicalTrials.gov NIH. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03140085."},{"key":"e_1_3_1_131_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168380"},{"key":"e_1_3_1_132_2","doi-asserted-by":"publisher","DOI":"10.3390\/antib7010005"},{"key":"e_1_3_1_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.10.052"},{"key":"e_1_3_1_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.001"},{"key":"e_1_3_1_135_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix315"},{"key":"e_1_3_1_137_2","doi-asserted-by":"crossref","unstructured":"Tsuji M Hackel M Echols R Yamano Y Sahm DF. 2017. In vitro activity of cefiderocol against globally collected carbapenem-resistant Gram-negative bacteria isolated from urinary tract source: SIDERO-CR-2014\/2016 abstr 1199. IDWeek 2017 4 to 8 October 2017 San Diego CA.","DOI":"10.1093\/ofid\/ofx163.895"},{"key":"e_1_3_1_138_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03098-15"},{"key":"e_1_3_1_139_2","doi-asserted-by":"crossref","unstructured":"Fyfe C Leblanc G Sutcliffe J Grossman T. 2016. Eravacycline is active against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii isolates in the FDA-CDC\nantimicrobial resistance isolate bank panels abstr 1844 IDWeek 2016 26 to 30 October 2017 New Orleans LA.","DOI":"10.1093\/ofid\/ofw172.1392"},{"key":"e_1_3_1_140_2","volume-title":"Abstr 27th Eur Cong Clin Microbiol Infect Dis","author":"Morrissey I","year":"2017","unstructured":"Morrissey I, Bassetti M, Magnet S, Hawser S, Olesky M, Fyfe C. 2017. In vitro activity of eravacycline and comparators against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae, including carbapenem- resistant and ESBL phenotype subgroups, collected from European hospitals in 2015, abstr P-1260. Abstr 27th Eur Cong Clin Microbiol Infect Dis, 22 to 25 April 2017, Vienna, Austria."},{"key":"e_1_3_1_141_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"e_1_3_1_142_2","volume-title":"Abstr 27th Eur Cong Clin Microbiol Infect Dis","author":"Fyfe C","year":"2017","unstructured":"Fyfe C, Close B, Leblanc G, Newman J. 2017. TP-6076 is active against carbapenem- and polymyxin-resistant Enterobacteriaceae and Acinetobacter baumannii isolates in the FDA-CDC antimicrobial isolate bank panels, abstr P-1365. Abstr 27th Eur Cong Clin Microbiol Infect Dis, 22 to 25 April 2017, Vienna, Austria."},{"key":"e_1_3_1_143_2","doi-asserted-by":"crossref","unstructured":"Barnes MD Christopher BR Joseph RD Van Den Akker F Bonomo RA. 2017. The novel \u03b2-lactamase inhibitor ETX-2514 in combination with sulbactam effectively inhibits Acinetobacter baumannii abstr 1204. IDWeek 2017 4 to 8 October 2017 San Diego CA.","DOI":"10.1093\/ofid\/ofx163.900"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01110-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01110-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:24:25Z","timestamp":1645478665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01110-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1128\/AAC.01110-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01110-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"2018-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01110-18"}}